Archive · 26 Jun 2025
Mounjaro KwikPen Approved in India for Diabetes, Weight Loss
Eli Lilly's Mounjaro, a medicine for diabetes and weight loss, now comes in a special pen called KwikPen in India.
This pen makes it easier for people to take their medicine once a week.
Mounjaro helps with diabetes and weight problems by affecting how the body uses sugar and controls appetite.
The KwikPen has different doses to help doctors give the right amount for each person.
This new pen is a step forward for those dealing with diabetes and weight issues.
Eli Lilly's Mounjaro, a drug for diabetes and weight loss, received regulatory approval in India in a KwikPen device.
The KwikPen is a multi-dose, pre-filled pen for once-weekly administration.
Mounjaro is a dual GIP and GLP-1 receptor agonist, used for Type 2 diabetes and chronic weight management.
The Mounjaro KwikPen will be available in six dose strengths.
This approval provides a more convenient way for patients to take their medication.
- Who
- Eli Lilly and people with Type 2 diabetes and obesity
- What
- Regulatory approval of Mounjaro KwikPen device in India
- When
- June 2025
- Where
- India
- Why
- To provide a more convenient way for patients to administer Mounjaro.
Advantage of Mounjaro KwikPen
No opposing view.
Convenience
Advantage of Mounjaro KwikPen
Increased convenience and ease of use for patients.
No opposing view.
No opposing view.
- Drug Name
- Mounjaro (tirzepatide)
- Company
- Eli Lilly and Company (India)
- Approved Device
- KwikPen
- Target Condition
- Type 2 diabetes and obesity
- Administration
- Once-weekly injection
- Dose Strengths
- 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
